Login to Your Account

A Breath of Fresh Air

Companies Look to Capture Part of Growing Respiratory Market

By Peter Winter

Monday, March 11, 2013

While another storm that hit the East Coast of the U.S. served to delay the scheduled FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting last week, South San Francisco-based Theravance Inc. and its partner GlaxoSmithKline plc, of London, shouldn't have too much longer to wait for what is predicted to be a positive review from the PADAC for their once-daily inhaled corticosteroid.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription